Skip to main content

Table 1 Demographic and clinical data

From: Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients

Patient Gender Age (years) Weight (kg) MV Cr Cl (mL/min) Infection focus Vasop Surgery Charlson SAPS II SOFA
1 M 73 77 No 76.7 Lung Yes No 4 26 4
2 F 58 55 Yes 25.0 Lung No No 3 44 5
3 F 77 65 No 66.7 Intra-abdominal No Yes 9 48 4
4 M 79 78 No 23.3 Intra-abdominal No Yes 6 38 2
5 F 78 85 Yes 81.7 Bacteremia No No 9 47 4
6 M 73 78 Yes 65.0 Unknown Yes Yes 5 43 8
7 F 76 80 Yes 43.3 Intra-abdominal Yes Yes 3 72 8
8 M 53 60 No 15.0 Skin/Soft tissue Yes No 6 34 6
9 F 71 90 Yes NA Intra-abdominal No Yes 6 37 3
10 M 41 80 Yes 116.7 Intra-abdominal No No 1 35 5
11 M 51 70 Yes 41.7 Lung Yes No 4 50 9
12 F 90 75 Yes NA Central nervous system No Yes 6 58 6
13 M 34 63 Yes 95.0 Lung No No 0 32 2
14 M 67 80 Yes 226.7 Lung No No 3 47 4
15 F 76 100 No 51.7 Intra-abdominal No Yes 3 47 2
Median [IQR]   73 [21] 78 [12.5]   65.0 (40)     4 [3] 44 [11.5] 4 [2.5]
  1. Surgery was considered when was performed in the last 24 h before patients’ admission to the Intensive Care Unit. M- Male; F-Female; MV – Invasive mechanical ventilation; Cr Cl – Creatinine Clearance; Vasop – Vasopressors; Charlson – Charlson comorbidity score; SAPS II – Simplified acute physiology score II; SOFA – Sequential organ failure assessment score; IQR – Interquartile range; NA-Not available.